The cost-effectiveness of Grazax® remains to be established and this product cannot be recommended as value for money at this point in time.

Cost effectiveness analysis of a universal infant hepatitis B vaccination programme in Ireland

Cost effectiveness analysis of a universal infant pneumococcal conjugate vaccination programme in Ireland.

The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.

The following reports were prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children.